LB-100

LIXTE Biotechnology Holdings amends its Development Collaboration Agreement with the Netherlands Cancer Institute and Oncode Institute, temporarily halting study activities until a Phase 1b clinical trial of LB-100 with a WEE1 inhibitor in metastatic colorectal cancer patients begins. The collaboration will resume once the first patient is dosed, continuing for one year with a revised annual budget of €100,000. Lixte also received a Nasdaq extension to meet its minimum stockholders’ equity requirement by February 18, 2025, aiming to raise up to $4 million through equity offerings. The company has revised its director compensation policy to equity-based remuneration.

Lixte Biotechnology Holdings, Inc. filed an Amendment No. 1 to Form S-1 Registration Statement with the SEC on November 1, 2024, for the offering of up to 1,895,734 Units, each consisting of one share of common stock or one pre-funded warrant to purchase one share of common stock and 1.25 common warrants to purchase one share of common stock, aiming to raise up to approximately $4,000,000. The offering is conducted on a reasonable best efforts basis, with WallachBeth Capital LLC as the exclusive placement agent. The company intends to use the net proceeds for working capital and general corporate purposes. The securities are offered at a fixed price, expected to be issued in a single closing, and the offering will end no later than November 30, 2024. The company faces risks related to development and regulatory approval of its product candidates, including potential clinical trial holds due to serious adverse events, and compliance with Nasdaq listing requirements.

Researchers use mitochondria transfer to boost T cell efficacy in cancer immunotherapy, turn mice transparent with food dye for real-time imaging, engineer Toxoplasma gondii to deliver proteins across the blood-brain barrier, activate oncogenic signaling to make cancer cells vulnerable to stress response inhibitors, and design 'antinuclear missile' antibodies to target cancer cell nuclei.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) received an extension from Nasdaq to meet the minimum stockholders’ equity requirement by February 18, 2025. The company plans to regain compliance through registered equity offerings, aiming to raise up to $4 million. Failure to meet the requirement could result in delisting, but Lixte has the option to appeal. Recent developments include changes in director compensation policy and a clinical trial agreement with the Netherlands Cancer Institute for their cancer drug, LB-100.

A new approach to cancer therapy involves stressing tumor cells with an activator, LB-100, then eliminating them with a WEE1 inhibitor, adavosertib. This 'paradoxical intervention' worked well in mice and is set for a phase 1b clinical trial for advanced colorectal cancer.